SCHEMBL1769924

SCHEMBL1769924

Cn1ccnc1S(=O)(=O)CC(=O)C1(c2ccc(Cl)cc2)CCCC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.41
HDAC4 P56524 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
NPSR1 Q6W5P4 2/20 0.40
GAA P10253 1/20 0.40
OPRM1 P35372 1/20 0.39
MAPT P10636 4/20 0.39
ALDH1A1 P00352 6/20 0.39
LMNA P02545 2/20 0.39
SIGMAR1 Q99720 1/20 0.38
QPCT Q16769 1/20 0.38
MAPK1 P28482 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12596442 0.99 HSD11B1 (0.43) HSD11B1HDAC4SMN1; SMN2NPSR1GAA
SCHEMBL1769984 0.98 HSD11B1 (0.41) HSD11B1HDAC4SMN1; SMN2NPSR1GAA
SCHEMBL1770266 0.95 OPRM1 (0.40) HSD11B1SMN1; SMN2GAAOPRM1ALDH1A1
SCHEMBL1770056 0.76 ALDH1A1 (0.59) SMN1; SMN2GAAMAPTALDH1A1LMNA
SCHEMBL6203065 0.76 ALDH1A1 (0.54) HSD11B1SMN1; SMN2GAAMAPTALDH1A1
SCHEMBL1770094 0.76 ALDH1A1 (0.58) HSD11B1SMN1; SMN2GAAMAPTALDH1A1
SCHEMBL12648861 0.75 ALDH1A1 (0.36) HSD11B1SMN1; SMN2NPSR1OPRM1ALDH1A1
SCHEMBL1770390 0.75 POLB (0.48) HSD11B1HDAC4ALDH1A1LMNANPC1
SCHEMBL1770067 0.75 HSD11B1 (0.40) HSD11B1HDAC4SMN1; SMN2NPSR1OPRM1
SCHEMBL1770153 0.74 ALDH1A1 (0.59) SMN1; SMN2GAAMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
WO-2009106817-A2 COMPOUND STERIX LIMITED (GB) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885HDAC4 1338/4885SMN1; SMN2 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.